NASDAQ$PODD
Insulet Corp. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Insulet's Q4 2022 revenue increased by 20% year-over-year, driven by strong Omnipod growth, particularly in the U.S.
Insulet Corporation reported a strong fourth quarter in 2022, with revenue reaching $369.7 million, a 20.1% increase compared to the previous year. The growth was primarily fueled by a 32.8% increase in total Omnipod revenue, with significant contributions from the U.S. market. The company's strategic priorities and the commercial launch of Omnipod 5 contributed to the positive results.
- Q4 2022 revenue increased by 20.1% year-over-year to $369.7 million.
- Total Omnipod revenue increased by 32.8% year-over-year.
- U.S. Omnipod revenue increased by 45.0% year-over-year.
- Adjusted EBITDA was $71.4 million, representing 19.3% of revenue.
Headline financials
Revenue & EPS history
Insulet · Revenue · Quarterly
$370M
Revenue by segment
Insulet · $370M total across 3 segments · Q4 2022
- U.S. Omnipod$276M+45.0%74.7%
- International Omnipod$90.2M+5.7%24.4%
- Drug Delivery$3.3M-89.7%0.9%
Forward guidance
The Company expects revenue growth of 11% to 14% for the quarter ending March 31, 2023. For the year ending December 31, 2023, the Company expects gross margin of 65% to 66% and operating margin of high-single digits.
Tailwinds
- Total Omnipod revenue growth of 22% to 25% for the quarter ending March 31, 2023.
- U.S. Omnipod revenue growth of 33% to 36% for the quarter ending March 31, 2023.
- Total Omnipod revenue growth of 17% to 22% for the year ending December 31, 2023.
- U.S. Omnipod revenue growth of 21% to 26% for the year ending December 31, 2023.
- Gross margin of 65% to 66% for the year ending December 31, 2023.
Headwinds
- Drug Delivery revenue decline of (100)% to (95)% for the quarter ending March 31, 2023.
- International Omnipod revenue growth of 4% to 7% for the quarter ending March 31, 2023.
- Drug Delivery revenue decline of (55)% to (45)% for the year ending December 31, 2023.
- International Omnipod revenue growth of 6% to 10% for the year ending December 31, 2023.
- Operating margin of high-single digits for the year ending December 31, 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+3.0%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+5.2%
Avg return
30 days after
65%
41 / 63 earnings
Positive
+20.7%
Q1 2025
Best reaction
-16.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.1% | +3.8% | +1.4% | |
| Q4 2025 | +3.5% | +1.2% | -7.8% | |
| Q3 2025 | +2.8% | +3.8% | -3.2% | |
| Q1 2025 | +20.7% | +25.1% | +21.3% | |
| Q4 2024 | -1.9% | -6.1% | -6.9% | |
| Q3 2024 | +12.0% | +15.0% | +10.9% | |
| Q2 2024 | -4.3% | +2.2% | +12.8% | |
| Q1 2024 | -5.5% | -1.9% | +9.0% | |
| Q4 2023 | -4.3% | -13.4% | -14.6% | |
| Q3 2023 | +18.1% | +17.5% | +39.6% | |
| Q2 2023 | -11.9% | -13.6% | -31.6% | |
| Q1 2023 | +2.4% | -0.4% | -12.4% | |
| Q4 2022 | +2.3% | -4.0% | +7.8% | |
| Q3 2022 | +19.6% | +16.3% | +17.7% | |
| Q2 2022 | +2.4% | -0.8% | -2.5% | |
| Q1 2022 | -16.8% | -23.0% | -13.9% | |
| Q4 2021 | +8.9% | +12.9% | +7.4% | |
| Q3 2021 | -1.3% | +2.0% | -15.6% | |
| Q2 2021 | -1.3% | +0.1% | +8.4% | |
| Q1 2021 | -11.4% | -13.0% | +2.8% | |
| Q4 2020 | +2.3% | +1.0% | +1.0% | |
| Q3 2020 | +14.6% | +14.4% | +16.0% | |
| Q2 2020 | +1.1% | -7.7% | -4.9% | |
| Q1 2020 | +5.4% | +6.8% | -13.3% | |
| Q4 2019 | -13.2% | -8.4% | -14.2% | |
| Q3 2019 | +9.9% | +16.4% | +26.5% | |
| Q2 2019 | +18.4% | +26.0% | +30.0% | |
| Q1 2019 | +14.0% | +20.9% | +29.4% | |
| Q4 2018 | +5.1% | +7.7% | +6.6% | |
| Q3 2018 | +0.4% | -2.4% | -4.9% | |
| Q2 2018 | +2.4% | +2.6% | +24.3% | |
| Q1 2018 | -3.6% | -4.3% | +9.0% | |
| Q4 2017 | +3.6% | -1.1% | +8.6% | |
| Q3 2017 | +18.9% | +22.7% | +21.0% | |
| Q2 2017 | +6.5% | +8.6% | +15.5% | |
| Q1 2017 | -5.8% | -4.6% | +0.9% | |
| Q4 2016 | -5.2% | +0.7% | -7.2% | |
| Q3 2016 | +9.9% | +10.3% | +3.9% | |
| Q2 2016 | +18.5% | +23.3% | +22.2% | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | +9.0% | — | — | |
| Q3 2015 | +13.2% | — | — | |
| Q2 2015 | +10.0% | — | — | |
| Q1 2015 | -11.0% | — | — | |
| Q4 2014 | -4.5% | — | — | |
| Q3 2014 | +5.1% | — | — | |
| Q2 2014 | -2.2% | — | — | |
| Q1 2014 | -14.0% | — | — | |
| Q3 2013 | -3.4% | — | — | |
| Q2 2013 | +10.2% | — | — | |
| Q1 2013 | +12.0% | — | — | |
| Q4 2012 | +9.3% | — | — | |
| Q3 2012 | +4.2% | — | — | |
| Q2 2012 | +4.8% | — | — | |
| Q1 2012 | +2.1% | — | — | |
| Q4 2011 | -3.5% | — | — | |
| Q3 2011 | +0.5% | — | — | |
| Q2 2011 | +2.9% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q4 2010 | -2.0% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q2 2010 | +0.3% | — | — | |
| Q1 2010 | +11.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro